rs641738C>T nearMBOAT7is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
View/ Open
Date
2021-01Author
Teo, Kevin
Abeysekera, Kushala W.M.
Adams, Leon
Aigner, Elmar
Anstee, Quentin M.
Banerjee, Rajarshi
Basu, Priyadarshi
Berg, Thomas
Bhatnagar, Pallav
Buch, Stephan
Canbay, Ali
Caprio, Sonia
Chatterjee, Ankita
Chen, Yii-Der Ida
Chowdhury, Abhijit
Daly, Ann K.
Datz, Christian
De Gracia Hahn, Dana
DiStefano, Johanna K.
Dong, Jiawen
Duret, Amedine
EU-PNAFLD Investigators
Emdin, Connor
Fairey, Madison
Gerhard, Glenn S.
GOLD Consortium
Guo, Xiuqing
Hampe, Jochen
Hickman, Matthew
Heintz, Lena
Hudert, Christian
Hunter, Harriet
Kelly, Matt
Kozlitina, Julia
Krawczyk, Marcin
Lammert, Frank
Langenberg, Claudia
Lavine, Joel
Li, Lin
Lim, Hong Kai
Loomba, Rohit
Luukkonen, Panu K.
Melton, Phillip E.
Mori, Trevor A.
Palmer, Nicholette D.
Parisinos, Constantinos A.
Pillai, Sreekumar G.
Qayyum, Faiza
Reichert, Matthias C.
Romeo, Stefano
Rotter, Jerome I.
Im, Yu Ri
Santoro, Nicola
Schafmayer, Clemens
Speliotes, Elizabeth K.
Stender, Stefan
Stickel, Felix
Still, Christopher D.
Strnad, Pavel
Taylor, Kent D.
Tybjærg-Hansen, Anne
Umano, Giuseppina Rosaria
Utukuri, Mrudula
Valenti, Luca
Wagenknecht, Lynne E.
Wareham, Nicholas J.
Watanabe, Richard M.
Wattacheril, Julia
Yaghootkar, Hanieh
Yki-Järvinen, Hannele
Young, Kendra A.
Mann, Jake P.
Metadata
Show full item record
Journal of Hepatology 74(1) : 20-30 (2021)
Abstract
Background & Aims: A common genetic variant near MBOAT7 (rs641738C>T) has been previously associated with hepatic fat and advanced histology in NAFLD; however, these findings have not been consistently replicated in the literature. We aimed to establish whether rs641738C>T is a risk factor across the spectrum of NAFLD and to characterise its role in the regulation of related metabolic phenotypes through a meta-analysis.
Methods: We performed a meta-analysis of studies with data on the association between rs641738C>T genotype and liver fat, NAFLD histology, and serum alanine aminotransferase (ALT), lipids or insulin. These included directly genotyped studies and population-level data from genome-wide association studies (GWAS). We performed a random effects meta-analysis using recessive, additive and dominant genetic models.
Results: Data from 1,066,175 participants (9,688 with liver biopsies) across 42 studies were included in the meta-analysis. rs641738C>T was associated with higher liver fat on CT/MRI (+0.03 standard deviations [95% CI 0.02-0.05], p(z) = 4.8x10(-5)) and diagnosis of NAFLD (odds ratio [OR] 1.17 [95% CI 1.05-1.3], p(z) = 0.003) in Caucasian adults. The variant was also positively associated with presence of advanced fibrosis (OR 1.22 [95% CI 1.03-1.45], p(z) = 0.021) in Caucasian adults using a recessive model of inheritance (CC + CT vs. TT). Meta-analysis of data from previous GWAS found the variant to be associated with higher ALT (p(z) = 0.002) and lower serum triglycerides (p(z) = 1.5x10(-4)). rs641738C>T was not associated with fasting insulin and no effect was observed in children with NAFLD.
Conclusions: Our study validates rs641738C>T near MBOAT7 as a risk factor for the presence and severity of NAFLD in individuals of European descent.
Lay summary: Fatty liver disease is a common condition where fat builds up in the liver, which can cause liver inflammation and scarring (including 'cirrhosis'). It is closely linked to obesity and diabetes, but some genes are also thought to be important. We did this study to see whether one specific change ('variant') in one gene ('MBOAT7') was linked to fatty liver disease. We took data from over 40 published studies and found that this variant near MBOAT7 is linked to more severe fatty liver disease. This means that drugs designed to work on MBOAT7 could be useful for treating fatty liver disease.